ClinicalTrials.gg
CompletedNCT04571060Updated Apr 24, 2023Results posted

Randomized Trial in Adult Participants With Acute Migraines

A Phase 3 interventional study of Zavegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 94 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-24.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,978
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing zavegepant in Migraine Disorders — 4 open to participants now, 4 under way, none of them phase 3. zavegepant · Migraine Disorders.

Enrollment
2nd of 12
1,978 · median 225
Started
2020
with 1 other
Phase 3
3 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing zavegepant in Migraine Disorders, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 3rd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

4 of the 12 studies testing zavegepant in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About zavegepant

zavegepant: first FDA approval 2023 (ZAVZPRET). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing zavegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.

03

Conditions studied

  • Migraine

Keywords

  • Acute Migraine
  • Phonophobia
  • Photophobia
  • Nausea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has at least 1-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, including the following:

    1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age
    2. Migraine attacks, on average, lasting about 4-72 hours if untreated
    3. Not more than 8 attacks of moderate to severe intensity per month within the last 3 months
    4. At least 2 consistent migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening period
    5. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period.
    6. Participants on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change during the course of the study.
    7. Participants with for use of triptans may be included provided they meet all other study entry criteria.
  2. Male and Female participants ≥18 years of age.

Exclusion criteria

Exclusion Criteria:

  1. Participant with a history of disease
  2. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening.
  3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however participants can be included who have stable hypertension and/or diabetes for at least 3 months prior to being enrolled).
  4. Participants with major depressive episode within the last 12 months, major depressive disorder or any anxiety disorder requiring more than 1 medication for each disorder.
  5. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or participants who have met criteria for any significant substance use disorder within the past 12 months.
  6. History of nasal surgery in the 6 months.
  7. Evidence at screening of significant nasal conditions that may affect the administration or absorption of the nasal product (e.g. severe septum deviation, nasal deformity or blockage, inflammation, perforation, mucosal erosion or ulceration, polyposis, nasal trauma)
  8. Participation in any other clinical trial while participating in this clinical trial. Participation in a COVID-19 mRNA vaccine study (vaccine must be authorized under FDA emergency use authorization or approval) who are at least 30 days post last dose of the vaccine are permitted to be screened for this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,978 participants (actual)

Study arms

  • Experimental
    Zavegepant

    Participants administered a single intranasal dose of zavegepant 10 mg on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar Unidose System (UDS) liquid spray device.

    Drug: Zavegepant

  • Placebo comparator
    Placebo

    Participants administered a single intranasal dose of zavegepant matching placebo on occurrence of migraine with moderate or severe intensity within 45 days after randomization. The dose was administered using an Aptar UDS liquid spray device.

    Drug: Placebo

Interventions

  • One dose of zavegepant

    Also known as: BHV3500

  • DrugPlacebo

    One dose of matching placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Freedom From Pain at 2 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.

    Time frame: 2 hours post-dose

  2. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

    MBS was reported as nausea, photophobia, or phonophobia immediately before dosing using the eCOA handheld device. Symptom status (absent, present) was assessed post-dose using the eCOA handheld device separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at on-study migraine attack onset that was absent post-dose.

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 2 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

    Time frame: 2 hours post-dose

  2. Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose

    Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  3. Percentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose.

    Time frame: From 2 to 24 hours post-dose

  4. Percentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose.

    Time frame: From 2 to 48 hours post-dose

  5. Percentage of Participants With Sustained Pain Freedom From 2 Hours to 24 Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose.

    Time frame: From 2 to 24 hours post-dose

  6. Percentage of Participants With Sustained Pain Freedom From 2 Hours to 48 Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose.

    Time frame: From 2 to 48 hours post-dose

  7. Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

    Phonophobia (sensitivity to sound) status was measured as absent or present in the eCOA handheld device. Freedom from phonophobia was defined as phonophobia absent post-dose in the subset of participants with phonophobia present at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  8. Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

    Photophobia (sensitivity to light) status was measured as absent or present in the eCOA handheld device. Freedom from photophobia was defined as photophobia absent post-dose in the subset of participants with photophobia present at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  9. Percentage of Participants With Pain Relief at 60 Minutes Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

    Time frame: 60 minutes post-dose

  10. Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose

    Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) present at on-study migraine attack onset.

    Time frame: 60 minutes post-dose

  11. Percentage of Participants With Pain Relief at 30 Minutes Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

    Time frame: 30 minutes post-dose

  12. Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose

    Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

    Time frame: 30 minutes post-dose

  13. Percentage of Participants With Pain Relief at 15 Minutes Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

    Time frame: 15 minutes post-dose

  14. Percentage of Participants Who Were Able to Function Normally at 15 Minutes Post-dose

    Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

    Time frame: 15 minutes post-dose

  15. Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose

    Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eCOA handheld device) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin® Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (for example, metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the site on a case report form.

    Time frame: Through 24 hours post-dose

  16. Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose

    Nausea status was measured as absent or present in the eCOA handheld device. Freedom from nausea was defined as nausea absent post-dose in the subset of participants with nausea present at on-study migraine attack onset.

    Time frame: 2 hours post-dose

  17. Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours post-dose in the subset of participants with pain level of none at 2 hours post-dose.

    Time frame: From 2 hours to 48 hours post-dose

07

Results

Posted Mar 16, 2023

Participant flow

Participants were enrolled at 90 sites in the United States.

Participant flow — Overall Study
MilestoneZavegepant 10 mgPlacebo
Started703702
Treated629653
Efficacy analysis set participants623646
Completed622653
Not completed8149
Withdrew: Lost to follow-up from randomization to treatment179
Withdrew: Never treated migraine4736
Withdrew: Protocol violation42
Withdrew: Withdrawal by subject62
Withdrew: Lost to follow-up from treatment to end of study70

Outcome measures

PrimaryPercentage of Participants With Freedom From Pain at 2 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic clinical outcome assessment (eCOA) handheld device. Pain freedom was defined as pain level of none post-dose.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose23.6 (20.3 to 26.9)14.9 (12.1 to 17.6)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05.) · Stratified percentage difference: 8.8 · 95% CI 4.5 to 13.1
PrimaryPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

MBS was reported as nausea, photophobia, or phonophobia immediately before dosing using the eCOA handheld device. Symptom status (absent, present) was assessed post-dose using the eCOA handheld device separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at on-study migraine attack onset that was absent post-dose.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose39.6 (35.8 to 43.5)31.1 (27.5 to 34.7)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0012 (Threshold for significance at 0.05.) · Stratified percentage difference: 8.7 · 95% CI 3.4 to 13.9
SecondaryPercentage of Participants With Pain Relief at 2 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 2 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Pain Relief at 2 Hours Post-dose58.7 (54.9 to 62.6)49.7 (45.8 to 53.5)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0012 (Threshold for significance at 0.05.) · Stratified percentage difference: 9.0 · 95% CI 3.6 to 14.5
SecondaryPercentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose

Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose35.8 (31.9 to 39.7)25.6 (22.1 to 29.1)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0001 (Threshold for significance at 0.05.) · Stratified percentage difference: 10.2 · 95% CI 5.0 to 15.5
SecondaryPercentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose.

Time frame:
From 2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose40.6 (36.8 to 44.5)33.0 (29.3 to 36.6)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0048 (Threshold for significance at 0.05.) · Stratified percentage difference: 7.6 · 95% CI 2.3 to 12.9
SecondaryPercentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose.

Time frame:
From 2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose36.1 (32.3 to 39.9)29.6 (26.0 to 33.1)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0130 (Threshold for significance at 0.05.) · Stratified percentage difference: 6.5 · 95% CI 1.4 to 11.7
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 Hours to 24 Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose.

Time frame:
From 2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 Hours to 24 Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 Hours to 24 Post-dose14.6 (11.8 to 17.4)9.8 (7.5 to 12.0)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0076 (Threshold for significance at 0.05.) · Stratified percentage difference: 4.9 · 95% CI 1.3 to 8.5
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 Hours to 48 Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose.

Time frame:
From 2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 Hours to 48 Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 Hours to 48 Post-dose12.4 (9.8 to 14.9)8.7 (6.5 to 10.8)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0308 (Threshold for significance at 0.05.) · Stratified percentage difference: 3.7 · 95% CI 0.3 to 7.1
SecondaryPercentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

Phonophobia (sensitivity to sound) status was measured as absent or present in the eCOA handheld device. Freedom from phonophobia was defined as phonophobia absent post-dose in the subset of participants with phonophobia present at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose41.0 (36.3 to 45.8)32.7 (28.2 to 37.2)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0123 (Threshold for significance at 0.05.) · Stratified percentage difference: 8.3 · 95% CI 1.8 to 14.9
SecondaryPercentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

Photophobia (sensitivity to light) status was measured as absent or present in the eCOA handheld device. Freedom from photophobia was defined as photophobia absent post-dose in the subset of participants with photophobia present at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose37.1 (33.1 to 41.1)28.5 (24.9 to 32.2)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0018 (Threshold for significance at 0.05.) · Stratified percentage difference: 8.6 · 95% CI 3.2 to 14.1
SecondaryPercentage of Participants With Pain Relief at 60 Minutes Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

Time frame:
60 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 60 Minutes Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Pain Relief at 60 Minutes Post-dose43.3 (39.4 to 47.2)37.3 (33.6 to 41.0)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0293 (Threshold for significance at 0.05.) · Stratified percentage difference: 6.0 · 95% CI 0.6 to 11.4
SecondaryPercentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose

Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) present at on-study migraine attack onset.

Time frame:
60 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose20.2 (16.9 to 23.5)15.5 (12.6 to 18.4)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0362 (Threshold for significance at 0.05.) · Stratified percentage difference: 4.7 · 95% CI 0.3 to 9.1
SecondaryPercentage of Participants With Pain Relief at 30 Minutes Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

Time frame:
30 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 30 Minutes Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Pain Relief at 30 Minutes Post-dose30.5 (26.9 to 34.1)20.3 (17.2 to 23.4)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05.) · Stratified percentage difference: 10.2 · 95% CI 5.5 to 15.0
SecondaryPercentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose

Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

Time frame:
30 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose10.5 (8.0 to 13.0)6.1 (4.1 to 8.0)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0059 (Threshold for significance at 0.05.) · Stratified percentage difference: 4.4 · 95% CI 1.3 to 7.6
SecondaryPercentage of Participants With Pain Relief at 15 Minutes Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relief was defined as pain level of none or mild.

Time frame:
15 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 15 Minutes Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Pain Relief at 15 Minutes Post-dose15.9 (13.0 to 18.8)8.0 (6.0 to 10.1)
Statistical analysis
  • Zavegepant 10 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.05.) · Stratified percentage difference: 7.8 · 95% CI 4.2 to 11.3
SecondaryPercentage of Participants Who Were Able to Function Normally at 15 Minutes Post-dose

Functional disability level was assessed on a 4-point scale (normal function, mildly impaired, severely impaired, requires bedrest) using the eCOA handheld device. Normal function was defined as a functional disability level of normal post-dose in the subset of participants with functional disability (mildly impaired, severely impaired, requires bedrest) at on-study migraine attack onset.

Time frame:
15 minutes post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Able to Function Normally at 15 Minutes Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants Who Were Able to Function Normally at 15 Minutes Post-dose3.3 (1.9 to 4.8)2.0 (0.9 to 3.2)
SecondaryPercentage of Participants With Rescue Medication Use Within 24 Hours Post-dose

Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eCOA handheld device) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin® Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (for example, metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the site on a case report form.

Time frame:
Through 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose29.7 (26.1 to 33.3)35.8 (32.1 to 39.5)
SecondaryPercentage of Participants With Freedom From Nausea at 2 Hours Post-dose

Nausea status was measured as absent or present in the eCOA handheld device. Freedom from nausea was defined as nausea absent post-dose in the subset of participants with nausea present at on-study migraine attack onset.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose52.4 (47.3 to 57.4)50.9 (46.0 to 55.7)
SecondaryPercentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eCOA handheld device. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours post-dose in the subset of participants with pain level of none at 2 hours post-dose.

Time frame:
From 2 hours to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose
Percentage of participantsZavegepant 10 mgPlacebo
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose40.8 (32.9 to 48.8)35.4 (25.8 to 45.0)

Adverse events

Collected over Adverse events were assessed from study drug dosing up to the end of the study (up to 55 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant 10 mg0/629 (0%)0/629 (0%)129/629 (20.5%)
Placebo0/653 (0%)0/653 (0%)31/653 (4.7%)
Most frequent other events
Most frequent other events
EventZavegepant 10 mgPlacebo
DysgeusiaNervous system disorders129/62931/653

Baseline characteristics

Treated participants included enrolled participants who took the study drug (zavegepant or placebo).

Age, Continuous
Age, Continuous(years)Zavegepant 10 mgPlaceboTotal
Mean40.9 ± 13.1940.7 ± 13.4640.8 ± 13.32
Sex: Female, Male
Sex: Female, Male(Participants)Zavegepant 10 mgPlaceboTotal
Female5085511059
Male121102223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zavegepant 10 mgPlaceboTotal
Hispanic or Latino114146260
Not Hispanic or Latino5155071022
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zavegepant 10 mgPlaceboTotal
American Indian or Alaska Native022
Asian211637
Native Hawaiian or Other Pacific Islander213
Black or African American8684170
White5155451060
More than one race5510
Unknown or Not Reported000
Prophylactic Migraine Medication Use at Randomization
Prophylactic Migraine Medication Use at Randomization(Participants)Zavegepant 10 mgPlaceboTotal
Yes8883171
No5415701111
08

Study locations

94 sites
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Coastal Clinical Research, LLC, An AMR Co.
    Mobile, Alabama 36608, United States
  • MD First Research
    Chandler, Arizona 85286, United States
  • Tucson Neuroscience Research
    Tucson, Arizona 85710, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Axiom Research, LLC
    Colton, California 92324, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Clinical Research Institute
    Los Angeles, California 90404, United States
  • Wr-Pri, Llc
    Newport Beach, California 92660, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • CT Clinical Research
    Cromwell, Connecticut 06416, United States
  • Ki Health Partners, LLC dba New England Institute for Clinical Research
    Stamford, Connecticut 06095, United States
  • Neurology Offices of South Florida
    Boca Raton, Florida 33428, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Multi-Specialty Research Associates, Inc.
    Lake City, Florida 32055, United States
  • Meridien Research
    Lake Mary, Florida 32746, United States
  • AppleMed Research Group, LLC
    Miami, Florida 33155, United States
  • The Neurology Research Group
    Miami, Florida 33176, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32819, United States
  • Complete Health Research
    Ormond Beach, Florida 32174, United States
  • Ideal Clinical Research
    Pembroke Pines, Florida 33026, United States
  • Clinical Research Center of Florida
    Pompano Beach, Florida 33060, United States
  • Clin-Med Research & Development, LLC
    South Miami, Florida 33143, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • JSV Clinical Research Study, Inc.
    Tampa, Florida 33634, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Meridian Clinical Research, LLC
    Savannah, Georgia 31406, United States
  • Northwest Clinical Trials Inc.
    Boise, Idaho 83704, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Healthcare Research Network II, LLC
    Flossmoor, Illinois 60422, United States
  • Fort Wayne Neurological Center
    Fort Wayne, Indiana 46804, United States
  • Collective Medical Research
    Prairie Village, Kansas 66208, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67205, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Crescent City Headache and Neurology Center
    Chalmette, Louisiana 70043, United States
  • DelRicht Research
    New Orleans, Louisiana 70124, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Community Clinical Research Network
    Marlborough, Massachusetts 01752, United States
  • Boston Neuro Research Center
    South Dartmouth, Massachusetts 02747, United States
  • Medvadis Research Corporation
    Waltham, Massachusetts 02451, United States
  • Michigan Headache and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Sundance Clinical Research, LLC
    Saint Louis, Missouri 63141, United States
  • StudyMetrix Research
    Saint Peters, Missouri 63303, United States
  • Clinvest Research LLC
    Springfield, Missouri 65810, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • Montefiore Medical Center: Headache Center
    Bronx, New York 10461, United States
  • Regional Clinical Research
    Endwell, New York 13760, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Fieve Clinical Research, Inc
    New York, New York 10017, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Headache Wellness Center
    Greensboro, North Carolina 27405, United States
  • PharmQuest LLC
    Greensboro, North Carolina 27408, United States
  • PMG of Raleigh, LLC
    Raleigh, North Carolina 27609, United States
  • Wilmington Health, PLLC
    Wilmington, North Carolina 28401, United States
  • Hometown Urgent Care & Research/ Wellnow
    Cincinnati, Ohio 45215, United States
  • Hometown Urgent Care and Research
    Columbus, Ohio 43214, United States
  • Hometown Urgent Care and Research
    Dayton, Ohio 45424, United States
  • The Orthopedic Foundation
    New Albany, Ohio 43054, United States
  • OK Clinical Research LLC
    Edmond, Oklahoma 73034, United States
  • Tekton Research, Inc.
    Yukon, Oklahoma 73099, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Preferred Primary Care Physicians, Inc.
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians, Inc.
    Union, Pennsylvania 15401, United States
  • MD First Research
    Lancaster, South Carolina 29720, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Donald J. Garcia, Jr, MD, PA
    Austin, Texas 78737, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Red Star Research LLC
    Lake Jackson, Texas 77566, United States
  • Clinical Trials of Texas, Inc. (CTT)
    San Antonio, Texas 78229, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Alpine Medical Group
    Salt Lake City, Utah 84107, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
  • Health Research of Hampton Roads, Inc.
    Newport News, Virginia 23606, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Seattle Women's: Health, Research, Gynecology
    Seattle, Washington 98105, United States
  • Clinical Investigation Specialist, Inc.
    Kenosha, Wisconsin 53144, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Oct 2021, 11 months.

Results were first posted in Mar 2023, 1 year 5 months after primary completion. A results delay was requested in Sep 2022.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 11 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2020
First posted
Sep 30, 2020
StartActual
Oct 27, 2020
Primary completionActual
Oct 10, 2021
CompletionActual
Oct 22, 2021
Results delay requested
Sep 21, 2022
Results first posted
Mar 16, 2023
Last update
Apr 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04571060
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Oct 27, 2020
Primary completion
Oct 10, 2021
Completion
Oct 22, 2021
Results posted
Mar 16, 2023
Last update
Apr 24, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion